32 / 35
Healthcare stakeholders are unclear about
the clinical utility of NGS
–
It remains to be proven whether NGS leads to more appropriate use of
targeted agents.
•
Concerns:
–
Only a subset of patients have tumours harbouring specific actionable
alterations that directly influence the choice of treatment.
–
Cost: it could be an expense addition rather than an affordable
alternative.
–
Definition of “actionability” varies widely across studies and
institutions (30% - 94%)
1
.
–
Organized information: without the organized collection of efficacy or
AEs,
each patient could be a clinical trial of a patient
2
1
Berger M, Nat Rev 2018
,
2
Stinchcombe T. et al, Ann Oncol 2017